Apollomics and launxp announce development and commercialization agreement for vebreltinib

Foster city, calif. and taipei, taiwan, march 31, 2025 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and launxp international co., ltd., an affiliate of launxp biomedical co., ltd. (two: 6876) (“launxp”), announced today that the parties have entered into an agreement for the development and commercialization in asia (excluding mainland china, hong kong and macau) (the “launxp territory”) of vebreltinib, apollomics' proprietary c-met inhibitor, in combination with an egfr inhibitor (“egfri”) for the treatment of nsclc. the egfri class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of nsclc and other tumor types.
APLM Ratings Summary
APLM Quant Ranking